10084-TB-2 IN VITRO CHARACTERIZATION OF COMBINATION THERAPY IN GENETICALLY-ENGINEERED MURINE DIFFUSE MIDLINE GLIOMA MODELS

Yusuke Tomita, Nozomu Takata, Oren Becher · 2023

Read 10084-TB-2 IN VITRO CHARACTERIZATION OF COMBINATION THERAPY IN GENETICALLY-ENGINEERED MURINE DIFFUSE MIDLINE GLIOMA MODELS by Yusuke Tomita, Nozomu Takata, Oren Becher (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10710603.txt.

Description

Diffuse midline glioma is a childhood brain cancer with no approved drug that extends life. Yusuke Tomita, Nozomu Takata, and Oren Becher built a mouse version of the disease in 2023. They switched on a growth signal, added the H3.3K27M mutation, and deleted the p53 gene in brainstem progenitor cells. The mice developed brainstem gliomas and lived a median of about 62 days.

From the tumor tissue the team grew a cell line in spheroid culture that kept the cancer's growth and invasive behavior; placed against a hindbrain organoid, the cells invaded it. Two drug classes suggested by molecular studies, a CDK4/6 blocker and a MEK blocker, were tested together. The pair showed a mild joint benefit in killing cells and triggering cell death. The authors offer the cell line as a tool for further drug testing against this cancer.

Catalog record

CREATORYusuke Tomita, Nozomu Takata, Oren Becher
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10710603

Browse the full library · About the Tower of Babel